Patent information
IP India · live recordAbstract
A topical delivery system comprising liposome encapsulating ascorbic acid wherein the liposome is formed from surfactants (e.g. phospholipids, cationic surfactants, anionic surfactants), sterols such as cholesterol, fatty acids and/ or hydrophobically modified surfaceactive polymers. The stable liposomal composition of ascorbic acid comprising, 0.01% to about 20% by weight aqueous solution of ascorbic acid wherein said ascorbic acid is pure and stable up to pH 7.0. A process for preparing the liposomal composition of ascorbic acid comprising (a) dissolving sterol, surface-active polymers, fatty acids in ethanol, (b) ascorbic acid solution in cooled boiled water, (c) adding the ascorbic acid solution obtained from step (b) to the mixture obtained from step (a) drop by drop under constant stirring condition, (d) mixing solution comprising surfactant and surface-active polymer and adding to the above mixture obtained from . step (c) under constant stirring and (e) adjusting pH of the solution to 6 to 7 using alkali.
Applicants
1Inventors
6Specification
Show full textCollapse
TECHNICAL FIELD OF THE INVENTION The present invention deals with a topical delivery of unstable cosmetic actives, more specifically ascorbic acid, in free form and a system comprising the same which is effective over all skin conditions (dry and normal). BACKGROUND OF THE PRIOR ART Ascorbic acid is one of the most important intracellular and extracellular antioxidant of body and important for controlling many cellular and enzymatic activities. Ascorbic acid increases the synthesis of collagen (act as cofactor for the enzymes, prolyl hydroxylase and lysyl hydroxylase for the synthesis of collagen) and maintains the amount of collagen by increasing the transcription rate of the genes associated with collagen synthesis. Several studies have shown that topical application of ascorbic acid and its derivatives can repair the photo-damaged skin. Darr, D., S. Combs, et al., "Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage", The British journal of dermatology 127(3): 247- 253 (1992); Darr. D., S. Dunston, et al., "Effectiveness of antioxidants (vitamin C and E) with and without sunscreens as topical photoprotectants." Acta dermato-venereologica 76(4): 264-268 (1996). Quevedo, W. C, T. J. Holstein, et al., "Inhibition of UVR-induced tanning and immunosuppression by topical applications of vitamins C and E to the skin of hairless (hr/hr) mice."" Pigment cell research /sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 13(2): 89-98, (2000); Meves, A., S. N. Stock, et al.. "Vitamin C derivative ascorbyl palmitate promotes ultraviolet-B-induced lipid peroxidation and cytotoxicity in keratinocytes." The Journal of investigative dermatology 119(5): 1103-1108. (2002% Moison, R. M. W. and G. M. J. Beijersbergen van Henegouwen, "Topical antioxidant vitamins C and E prevent UVB-radiation-induced peroxidation of eicosapentaenoic acid in pig skin.", Radiation research 157(4): 402-409,(2002) Moison, R. M. W., .1. M. Rijnkels, et al., "Topically applied vitamin C and cysteine derivatives protect against UVA-induced photodegradation of suprofen in ex vivo pigskin.", Photochemistry and photobiology 77(4): 343-348,(2003). Lin. F.-H., J.-Y. Lin, et al., "Ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin.", The Journal of • investigative dermatology 125(4): 826-832, (2005); Cho, H.-S., M.-H. Lee, et al., "Anti-wrinkling effects of the mixture of vitamin C, vitamin E, pycnogenol and evening primrose oil, and molecular mechanisms on hairless mouse skin caused by chronic ultraviolet B irradiation." Photodermatology. photoimmunology & photomedicine 23(5): 155-162, (2007);
Oresajo, C. T. Stephens, et al., "Protective effects of a topical antioxidant mixture containing vitamin C. ferulic acid, and phloretin against ultraviolet-induced photodamage in human skin.". Journal of cosmetic dermatology 7(4): 290-297, (2008); Raschke, T., U. Koop, et al., "Topical activity of ascorbic acid: from in vitro optimization to in vivo efficacy.", Skin pharmacology and physiology 17(4): 200-206, (2004). The main disadvantage of using ascorbic acid in solution is that it undergoes oxidation and produce dehydro-l.-ascorbic acid as well as many degradation products. Tsao, C.S., Young, M. A stabilised ascorbic acid solution, Med. Sci. Res. 24, 473-475, (1996). The oxidative degradation process can be accelerated by several factors, such as high storage temperatures, photo exposure, high pH values (>4.5) and the presence of dissolved oxygen. Roig, M.G., Rivera, Z.S.. Kennedy, J.F., A model study on rate of degradation of L-ascorbic acid during processing using home-produced juice concentrates. Int. J. Food Sci. Nutr. 46, 107-115 (1995); Miyake. N., Miok, K., Kurata, T., Formation mechanism of mono dehydro-L-ascorbic acid and superoxide anion in the autoxidation of L-ascorbic acid, Biosci. Biotech. Biochcm. 61. 1693-1695. (1997). In addition, the reaction of ascorbic acid with oxygen is strongly catalysed by metal ions, especially (Cupric and ferric ions) Niki, E., Vitamin C as an antioxidant. World Rev. Nutr. Diet 64, 1-30 (1991), Buettner, G.R., Jurkiewicz, B.A., Chemistry and Biochemistry of ascorbic acid. In: Cadenas, E„ Paker, L. (Eds.), Handbook of Antioxidants. Marcel Dekker, New York, pp. 91-115, (1996). In the contemporan scenario, one of the ways to stabilize ascorbic acid is by derivatizing it. The most common of these, sodium ascorbyl phosphate, magnesium ascorbyl phosphate and ascorbyl-6-palmitate are enzymatically converted to L -ascorbic acid in cell, organ culture (Nayama. S.. Takehana, M., Kanke, M., Itoh, S., Ogata, E., Kobayashi, S., Protective effects of sodium- L -ascorbyl-2 phosphate on the development of UVB-induced damage in cultured mouse skin. Biol. Pharm. Bull. 22, 1301-1305 (1999)) and/ or by ingestion; but do not efficiently increase skin levels of L -ascorbic acid after topical application (Pinnell, S.R., Yang. H.S.. Omar. M, Riviere, N.M., DeBuys, H.V., Walker, L.C., et al., Topical L -ascorbic acid: percutaneous absorption studies. Dermatol. Surg. 27, 137-142 (2001)). In addition, . derivatisation leads to a reduced antioxidant efficacy. Moreover, the conversion of derivative to its active form is mediated by in-situ enzymes, which are inactive in dry or damaged skin. The present invention elucidates the solution for delivering ascorbic acid by maintaining its inherent efficacy, applicable for all skin types.
Microfine particles of ascorbic acid was used to stabilize the same in anhydrous formulations, which in turn was utilizedfor studying the effect of the same on neocollagenesis and cytokeratin production in ex vivo human skin and the results showed neocollagenesis and increased production of cytokeratin (Heber, G.K., Markovic, B., Hayes, A., An immunohistological study of anhydrous topical ascorbic acid compositions on ex vivo human skin. J. Cosmet. Dermatol. 5. 150-156. (2006)). US 2005/ 220860Al teaches about cosmetic powders containing pure vitamin C by utilizing multi encapsulation method, which changes to liquid, when sprayed over skin and slight pressure is applied. The present invention stabilizes ascorbic acid in aqueous form, which does not require external pressure and spray of water to liquefy it. The present invention finds direct application for products in which there is no scope of applying shear forces (pressure) on the skin (viz; face mask) US 6020367 teaches a method for preparing stable, supersaturated solutions of ascorbic acid in polyol vesicles. It teaches supersaturated ascorbic acid at a concentration of upto 25% by weight of ascorbic acid stabilized inside polyol vehicle that has further been incorporated in liposome. Known processes making naturally photo-unstable compound such as ascorbic acid, includes providing shielding mechanisms such as optical filters, colored or shiny bottle and special packaging, which are cumbersome and not user friendly. Adapting this technology to cosmetics comprising ascorbic acid is not feasible as ascorbic acid oxidizes at pH 7.0. It has been surprisingly found that a chemical barrier between ascorbic acid and oxygen/optical stimuli by entrapping the ascorbic acid inside liposome and appropriately adjusting the internal and external pH stabilizes the active composition and delivers the same appropriately. OBJECT OF THE INVENTION It is an object of the invention to overcome the drawbacks of the prior art.
It is another object of the present invention to provide a topical delivery system, which prevents degradation of an unstable active (e.g. ascorbic acid aqueous solution at pH 7) by encapsulating with liposome, which builds a barrier between environment and active. It is another object of the present invention to provide system for improving the topical availability of active antioxidant in skin. It is yet another object of the present invention to provide system comprising pure ascorbic acid for cosmetic applications, which is stable for more than a month. It is further an object of the present invention to provide sustained topical delivery of antioxidant. It is further an object of the present invention to provide topical delivery of antioxidants (e.g. Ascorbic acid) in a wide concentration range as required by individual, which is not achievable by conventional ascorbic acid derivatives in presence of equivalent delivery systems. SUMMARY OF THE INVENTION A stable liposomal composition of ascorbic acid comprising, 0.01% to about 20% by weight aqueous solution of ascorbic acid in a liposome such that said ascorbic acid is pure and stable up to pH 7.0 in the said composition. A process for preparing the liposomal composition of ascorbic acid comprising a) dissolving phospholipids, sterol, surface-active polymers, fatty acids in Ethanol. b) solubilizing ascorbic acid in cooled boiled water c) adding the ascorbic acid solution obtained from step (b) to the mixture obtained from step (a) drop by drop under constant stirring condition. d) mixing solution comprising surfactant and polyol and adding to the above mixture obtained from step (c) under constant stirring. e) adjusting pH of the solution to 6 to 7 using alkali
BRIEF DESCRIPTION OF THE ACCOMPANYING FIGURES Figure. 1 illustrates the Stability of aqueous and liposomal form of ascorbic acid has been measured in different experimental conditions (pH 7 at ambient condition) for seven weeks. Figure. 2 illustrates the delivery of ascorbic acid from three different forms (aqueous form, liposomal form of ascorbic acid and aqueous form of sodium ascorbyl phosphate) to different skin depth Figure. 3 illustrates the anti-oxidant activity of the liposomal L-ascorbic acid and liposomal Na-ascorbyl phosphate in different skin depth Figure. 4 illustrates the kinetics of release of liposomal ascorbic acid in skin after application on volar forearm DETAILED DESCRIPTION OF THE INVENTION The present invention relates to delivery systems, more specifically, a phospholipid based liposomal formulation containing antioxidant for treating human skin. In the present invention stabilization of the aqueous solution of the active is achieved only by liposome, . whereas the prior art uses polyol vehicle irrespective of liposome usage for stability. This feature has not been recited by prior art. The inventors have tested the same for topical delivery and have found it to be stable for up to seven weeks. Specimens not subjected to this protocol normally starts degrading within 1 day. Skin lacking proper barrier function becomes dry due to the transepidermal water loss. The enzymes present in the epidermal layer become inactive due the absence of required level of skin hydration. Most of the antioxidant derivatives used in the skin care formulation needs to be enzymatically hydrolyzed to its active form. As the enzymes are not active for releasing the active form of the antioxidant from its derivatives, the activity of the same might be questionable. The present invention improves the availability of active antioxidant in skin compared to its derivative. The present invention improves the sustained release of antioxidant. Accordingly the present invention provides a topical delivery system comprising liposome encapsulating ascorbic acid. The liposome is formed from surfactants such as phospholipids,
cationic surfactants, anionic surfactants; sterols such as cholesterol; fatty acids and/ or hydrophobically modified surface-active polymers. The liposome formation was controlled by retarding movement of surfactant molecules in the viscous medium, thereby increasing the encapsulation efficiency for the ascorbic acid. The invention provides a water-soluble form of pure ascorbic acid, which is stable up to a pH 7.0 that is much beyond its natural stability at pH 3.0. The invention provides ascorbic acid . that is chemically pure and thus effective in cosmetic applications. The ascorbic acid can include one selected from the group comprising L-ascorbic acid, D-ascorbic acid. D-araboascorbic acid. L-araboascorbic acid and combinations thereof. Preferably, the ascorbic acid is L- ascorbic acid. The amount of ascorbic acid present in the aqueous solution is about 0.01% to about 20% by weight most preferably from 1% to 5% by weight. The surfactant in the present invention is selected from the group of phospholipids such as phosphotidycholine, phosphotidylethanolamine; cationic surfactants such as Dodecyl (C12), myryltoyl (C14). palmitoyl (C16) and stearyl (C18) trimethyl ammonium chloride (C12-18TC), Dodecyl (C12). myryltoyl (C14), palmitoyl (C16) and stearyl (C18) trimethyl ammonium bromide (C12-18TAB). Most preferably the surfactant is selected from phosphotidylcholine, phosphatidylethanolamine and CTC. The surfactant in the present invention is present in the amount of 0.01 to 10% by weight; preferably from 0.1 to 5% by weight ; most preferably from 0.1 to 1% by weight. The sterols in the present invention are selected from the group of phytosterols (e.g. stigmasterol. ergostcrols, sitosterols, campesterol) and cholesterol and their derivatives; most preferably the sterol is cholesterol. The sterol in the present invention is present in the amount of 0.1 to 30% by weight; preferably from 5 to 20% by weight; most preferably from 10 to 15% by weight.
1 he fatty acids in the present invention are selected from the group of long chain fatty acids, preferably straight chain fatty acids such as Myristic acid, Palmitic acid. Stearic acid, Arachidic acid: most preferably stearic acid and palmitic acid The Fatty acids in the present invention is present in the amount of 0.01 to 10% by weight; more preferably 1 to 8% by weight; most preferably 5 to 7% by weight. The surface-active polymers in the present invention is selected from the group of hydrophobically modified polymers such as hydrophobically modified polysaccharides, • hydrophobically modified polyols; preferably hydrophobically modified polyols and most preferably fatty acyl derivatives of polyols such as fatty acyl derivatives of polyethylene glycol, PEG22. The surface-active polymers in the present invention are present in the amount of 0.01 to 20% by weight; preferably 1 to 8% by weight and most preferably 5 to 8% by weight. Liposomal formulation of ascorbic acid of the present invention, when applied on skin of the volar forearm of different panelists showed good penetrability and anti oxidants activities over a period of 4 hrs. The ascorbic acid solution can be readily used in compositions containing other cosmetic and pharmaceutical agents, e.g., anti-fungals, vitamins, sunscreens, retinoids, antihistamines, depigmenting agents, anti-inflammatory agents, anesthetics, surfactants, emulsifiers, stabilizers, preservatives, antiseptics, emollients, thickeners, lubricants, humectants, chelating agents, fragrances, colorants and skin penetration enhancers. The present invention is used in any form of personal care (such as but not limited to creams, lotions, face mask, serums, face wash, wipes) formulations. The present systems can also be incorporated in other formulation containing sunscreens, fairness, conditioning, moisturizing. The invention is now described by way of illustrative non-limiting examples with reference to figures. Example 1 Formulation 1: Components of liposome:
The liposome is made of surfactants (4% by weight) (e.g. phospholipids, cationic surfactants, anionic surfactants), cholesterol (0.3% by weight), fatty acids (0.14% by weight), surface-active polymers (1% by weight) (e.g. hydrophobically modified polymers) and ascorbic acid 3.5% by weight. Ascorbic acid solution Ascorbic acid used is 3.5% L-ascorbic acid (obtained from Sigma-Aldrich, 99%purity) solubilized in cooled boiled deionized water. Example 2: Process Steps Method of Preparation of Liposomal ascorbic acid: To prepare a l00gm of liposomal solution containing 3.5%, by weight of ascorbic acid, , phospholipid (2% by weight), cholesterol (0.3% by weight), hydrophobically modified polymer (e.g. PEG-22) (1% by weight), fatty acids (e.g. Stearic acid) (0.14% by weight) were dissolved in Ethanol (5% by weight). L-Ascorbic Acid ( 3.5% by weight) solutions in cooled boiled water was added to the above mixer drop by drop (1 to 2mL/min) under constant stirring condition. Eight grams (8gm) of a mixed solution comprising of a cationic or anionic surfactant (e.g. 2% CTC-30) and polyol (e.g 6% glycerin) was added to the above mixture (8()gm) under constant stirring. The pH of the solution was adjusted to 6 to 7 using alkali (e.g. NaOH). The total weight was adjusted to 100gm by cooled boiled water. Example 3 Tape stripping test: The penetration and antioxidant activity of aqueous solution of ascorbic acid and liposomal ascorbic acid was determined using tape stripping. Known volume (20µl) of aqueous solution of ascorbic acid in water and ascorbic acid in liposomes were applied on the skin of volar fore arm and allowed to dry completely for 20minutes. Tape strips of samples were collected using adhesive tapes (Corneofix) from applied sites and unapplied site (baseline) after washing the sites with known volume of water. The tapes striped out were kept in centrifuge tubes (Eppendorf) and known volume of phosphate buffer saline (PBS) was added to all the tubes. All the tubes were vortexed vigorously for 20 sec to extract ascorbic acid in the buffer solution from the tapes. The absorbance was measured at 265nm spectrophotometrically. The concentration of ascorbic acid was calculated from the concentration Vs absorbance standard graph. The antioxidant activity of ascorbic acid from aqueous and from liposomal form in
Example 4: Comparative formulation: Ascorbic acid (AA) with /without liposome to show stability at pH 7 Stability of aqueous and liposomal form of ascorbic acid containing 3.5% by weight ascorbic acid (L- Ascorbic acid in liposomal and Free form) has been measured in different experimental conditions (pH 7 at ambient condition) for seven weeks, which is provided in figure I. Liposomal ascorbic acid was found to be stable compared to its aqueous solution form over seven weeks at ambient temperature. Example 5 Delivery of ascorbic acid from three different forms (aqueous form, liposomal form of ascorbic acid and aqueous form of sodium ascorbyl phosphate) to different skin depth The delivery of aqueous form, liposomal form of ascorbic acid containing 3.5% by weight ascorbic acid and aqueous form of the sodium ascorbyl phosphate in different skin depth was determined using tape-striping method as described earlier. The amount of ascorbic acid in each tape-strip was determined using DPPH assay As can be seen from the graph in figure 2, the liposomal form delivers significantly more amount of ascorbic acid at different skin depths, when compared to derivative and non-encapsulated form. Example 6 Comparison of the anti-oxidant activity of the liposomal L-ascorbic acid and liposomal Na-aseorbyl phosphate in different skin depth The antioxidant activity of the liposomal L-ascorbic acid containing 3.5% by weight ascorbic acid and liposomal Na-ascorbyl phosphate were compared after application in skin were determined using tape-stripping followed by DPPH free radical scavenging assay. Here
known volume of liposomal ascorbic acid solution and Sodium Ascorbyl Phosphate solution was applied on different regions of volar fore arm. The applied liquid solution was allowed to absorb into the skin for 20min. The sites were washed with fixed volume of distilled water and allowed to dry. Six different tape strips were taken from each site of application along with an unapplied site (baseline) and the actives were extracted in phosphate buffer. The percentage antioxidant activity in each extracted solution was determined from the measurement of the free radical scavenging activity of DPPH. The percentage of free radical scavenging activity of the liposomal L-ascorbic acid was higher than the liposomal Na-ascorbyl phosphate used for the study. It can be inferred from the data provided in figure 3 that ascorbic acid derivatives do not show significant anti-oxidant efficacy even when the penetration is enhanced by liposomal encapsulation. Example 7 Kinetics of Release of liposomal ascorbic acid in skin after application on volar forearm The delivery of ascorbic acid from liposome containing 3.5% by weight ascorbic acid to different skin depths over a period of time (4 to 5 hrs) was studied using tape-stripping method. The amount of ascorbic acid in skin was measured using DPPH scavenging assay. The results as provided in figure 4 showed that the DPPH scavenging activity for liposomal ascorbic acid persists more than four hours. On a five-hours study liposomal ascorbic acid showed free radical scavenging activity in all the five strips over baseline. The liposomal -ascorbic acid showed availability at different skin depths over a time line of four hours. Example 8 Efficacy of the present process over the conventional protocol of liposome preparation To check the efficacy of the present process over the conventional protocol of liposome preparation (Delivery system handbook for personal care and cosmetic products: technology . By Meyer R. Rosen. 2005), evaluation of the conventional methods of liposome preparation was done in-house. The data generated in-house for conventional protocol matches with the data reported in literature. The uses of these liposomes in formulation are limited due to their limited stability and encapsulation efficiency.
The liposome prepared in the present invention containing 3.5% by weight ascorbic acid has higher encapsulation efficiency. Besides the liposome is stable itself and remains stable when incorporated in formulation. Table I mentioned below aim at representing the differences of present invention from conventional protocol, along with their associated benefits:
We claim 1) A stable liposomal composition of ascorbic acid comprising, 0.01% to about 20% by weight aqueous solution of ascorbic acid in a liposome such that said ascorbic acid is pure and stable up to a pH 7.0 in the said composition. 2) The stable liposomal composition as claimed in claim 1, wherein said aqueous solution of ascorbic acid comprises preferably 1% to 5% by weight of ascorbic acid. 3) The stable liposomal composition as claimed in any of the claim 1 or 2, wherein said liposome comprises 0.01 to 10% by weight surfactants, 0.01 to 50% by weight sterol, 0.01 to 10% by weight fatty acids, 0.01 to 20% by weight surface-active polymers and combinations thereof 4) The stable liposomal composition as claimed in claim 3, wherein said surfactant is selected from phospholipids, cationic surfactants, and combinations thereof. 5) The stable liposomal composition as claimed in claim 4, wherein said phospholipids is selected from phosphotidylcholine and phosphotidylethanolamine 6) The stable liposomal composition as claimed in any of claim 4 or 5, wherein said cationic surfactants is selected from Dodecyl (C12), myryltoyl (C14), palmitoyl (C16)
and stearyl (C18) trimethyl ammonium chloride (C12-18TC), Dodecyl (C12), myryltoyl (C14). palmitoyl (C16) and stearyl (C18) trimethyl ammonium bromide (C12-18TAB) 7) The stable liposomal composition as claimed in any of claim 3 to 6, wherein said surfactants is present in the amount of 0.01 to 10% by weight; preferably 0.1 to 5% by weight: more preferably 0.1 to 1% by weight. 8) The stable liposomal composition as claimed in claim 3, wherein said sterol is selected from phytosterols, cholesterol and their derivatives and combinations thereof 9) The stable liposomal composition as claimed in claim 8, wherein said phytosterols is • • selected from stigmasterol, ergosterols, sitosterols and campesterol. 10) The stable liposomal composition as claimed in any of claim 3 or 8, wherein said sterol is cholesterol. 11) The stable liposomal composition as claimed in any of claim 3 and 8 to 10, wherein said sterol is present in the amount of 0.1 to 30% by weight, preferably 5 to 20% by weight, more preferably 10 to 15% by weight 12) The stable liposomal composition as claimed in claim 3, wherein said fatty acids are selected from long chain fatty acids and straight chain fatty acids 13) The stable liposomal composition as claimed in claim 12, wherein said straight chain fatty acids is selected from Myristic acid. Palmitic acid, Stearic acid. Arachidic acid 14) The stable liposomal composition as claimed in any of claim 12 or 13. wherein said straight chain fatty acids is selected from palmitic and stearic acids . 15) The stable liposomal composition as claimed in any of claim 3 and 12 to 14, wherein said fatty acid is present in the amount of 0.01 to 10% by weight, preferably from 1 to 8% by weight, more preferably from of 5 to 7% by weight 16) The stable liposomal composition as claimed in claim 3, wherein said surface-active polymers is hydrophobically modified polymers, selected from hydrophobicaly
modified polysaccharides, PEG22, preferably hydrophobically modified polyols and most preferably fatty acyl derivatives of polyols. 17) The stable liposomal composition as claimed in any claim 3 or 16 wherein the surface-active polymers are present in the amount of 0.01 to 20% by weight; preferably 1 to 8% by weight; more preferably 5 to 8% by weight. 18) The stable liposomal composition as claimed in any of the preceding claims wherein the said composition is a cosmetic composition. 19) A process for preparing the liposomal composition of ascorbic acid comprising a. dissolving sterol, surface-active polymers, fatty acids in ethanol. b. Dissolving ascorbic acid in cooled boiled water c. adding the ascorbic acid solution obtained from step (b) to the mixture obtained from step (a) drop by drop (I -2 ml/minute) under constant stirring condition. d. mixing solution comprising surfactant and polyol and adding to the above mixture obtained from step (c) under constant stirring. e. adjusting pH of the solution to 6 to 7 using alkali
A topical delivery system comprising liposome encapsulating ascorbic acid wherein the liposome is formed from surfactants (e.g. phospholipids, cationic surfactants, anionic surfactants), sterols such as cholesterol, fatty acids and/ or hydrophobically modified surfaceactive polymers. The stable liposomal composition of ascorbic acid comprising, 0.01% to about 20% by weight aqueous solution of ascorbic acid wherein said ascorbic acid is pure and stable up to pH 7.0. A process for preparing the liposomal composition of ascorbic acid comprising (a) dissolving sterol, surface-active polymers, fatty acids in ethanol, (b) ascorbic acid solution in cooled boiled water, (c) adding the ascorbic acid solution obtained from step (b) to the mixture obtained from step (a) drop by drop under constant stirring condition, (d) mixing solution comprising surfactant and surface-active polymer and adding to the above mixture obtained from . step (c) under constant stirring and (e) adjusting pH of the solution to 6 to 7 using alkali.